New hope for tough breast cancer: targeted drug shows promise in Late-Stage trial
NCT ID NCT06519370
First seen Jan 26, 2026 · Last updated May 06, 2026 · Updated 15 times
Summary
This study tests a new drug called FDA018-ADC against standard chemotherapy for people with advanced triple-negative breast cancer that has come back after taxane treatment. About 350 participants will be randomly assigned to receive either the new drug or a standard chemo chosen by their doctor. The main goals are to see if the new drug can delay cancer growth and improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.